

## List of publications

1. Matkó J, **Nagy P**, Panyi G, Vereb G, Bene L, Mátyus L, Damjanovich S: Biphasic effect of extracellular ATP on the membrane potential of mouse thymocytes. *Biochem Biophys Res Commun*, 191: 378-384. (1993) IF:3.312
2. Matkó J, Mátyus L, Szöllősi J, Bene L, Jenei A, **Nagy P**, Bodnár A, Damjanovich S: Analysis of cell surface molecular distributions and cellular signaling by flow cytometry. *J Fluorescence*, 4(4): 303-314. (1994) IF:0
3. van de Put FHMM, **Nagy P**, De Pont JJHM, Willems PHGM: Differences in uptake, storage and release properties between inositol trisphosphate-sensitive and -insensitive  $Ca^{2+}$  stores in permeabilized pancreatic acinar cells. *Cell Calcium*, 17: 85-96. (1995) IF:3.419
4. **Nagy P**, Panyi G, Jenei A, Bene L, Gáspár R Jr., Matkó J, Damjanovich S: Ion channel activities regulate transmembrane signaling in thymocyte apoptosis and T-cell activation. *Immunol Lett*, 44: 91-95. (1995) IF:1.241
5. Matkó J, **Nagy P**: Fluorescent lipid probes 12-AS and TMA-DPH report on purinergically induced fluidity changes in plasma membranes of lymphoid cells. *J Photochem Photobiol B. Biol*, 40: 120-125. (1997) IF:1.381
6. **Nagy P**, Bene L, Balázs M, Hyun WC, Lockett SJ, Chiang NY, Waldman F, Feuerstein BG, Damjanovich S, Szöllősi J: EGF-induced redistribution of erbB2 on breast tumor cells: Flow and image cytometric energy transfer measurements. *Cytometry*, 32: 120-131. (1998) IF:2.317
7. **Nagy P**, Vámosi G, Bodnár A, Lockett SJ, Szöllősi J: Intensity-based energy transfer measurements in digital imaging microscopy. *Eur Biophys J*, 27: 377-389. (1998) IF:1.829
8. **Nagy P**, Jenei A, Kirsch AK, Szöllősi J, Damjanovich S, Jovin TM: Activation- dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. *J Cell Sci*, 112: 1733-1741. (1999) IF:6.044
9. **Nagy P**, Jenei A, Damjanovich S, Jovin TM, Szöllősi J: Complexity of signal transduction mediated by erbB2: clues to the potential of receptor-targeted cancer therapy. *Pathol Oncol Res*, 5: 255-271. (1999) IF:0
10. Hederer RA, Gunterman C, Miller N, **Nagy P**, Szöllősi J, Damjanovich S, Hale G, Alexander DR: The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in T cells. *Int Immunol*, 12: 505-516. (2000) IF:3.13

11. **Nagy P**, Fehér T, Morga S, Matkó J: Apoptosis of murine thymocytes induced by extracellular ATP is dose- and cytosolic pH-dependent. *Immunol Lett*, 72: 23-30. (2000) IF:1.546
12. **Nagy P**, Mátyus L, Jenei A, Panyi G, Varga S, Matkó J, Szöllősi J, Gáspár R, Jovin TM, Damjanovich S: Cell fusion experiments reveal distinctly different association characteristics of cell-surface receptors. *J Cell Sci*, 114: 4063-4071. (2001) IF:6.213
13. Pfeiffer A, Böttcher A, Orsó E, Kapinsky M, **Nagy P**, Bodnár A, Spreitzer I, Liebisch G, Drobnik W, Gempel K, Horn M, Holmer S, Hartung T, Multhoff G, Schütz G, Schindler H, Ulmer AJ, Heine H, Stelter F, Schütt C, Rothe G, Szöllősi J, Damjanovich S, Schmitz G: Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. *Eur J Immunol*, 31: 3153-3164. (2001) IF:4.99
14. Dornan S, Sebestyén Z, Gamble J, **Nagy P**, Bodnár A, Alldridge L, Doe S, Holmes N, Goff LK, Beverley P, Szöllősi J, Alexander DR: Differential association of CD45 isoforms with CD4 and CD8 regulates the actions of specific pools of p56lck tyrosine kinase in T cell antigen receptor signal transduction. *J Biol Chem*, 277: 1912-1918. (2002) IF:6.696
15. Szöllősi J, **Nagy P**, Sebestyén Z, Damjanovich S, Park JW, Mátyus L: Applications of fluorescence resonance energy transfer for mapping biological membranes. *Rev Mol Biotechnol*, 82: 251-266. (2002) IF:0
16. Sebestyén Z, **Nagy P**, Horváth G, Vámosi G, Debets R, Gratama JW, Alexander DR, Szöllősi J: Long wavelength fluorophores and cell-by-cell correction for autofluorescence significantly improves the accuracy of flow cytometric energy transfer measurements on a dual-laser benchtop flow cytometer. *Cytometry*, 48: 124-135. (2002) IF:1.933
17. Vereb G Jr, **Nagy P**, Park JW, Szöllősi J: Signaling revealed by mapping molecular interactions: implications for ErbB-targeted cancer immunotherapies. *Clin Appl Immunol Rev*, 2: 169-186. (2002) IF:0
18. **Nagy P**, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S, Park JW, Jovin TM, Szöllősi J: Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. *J Cell Sci*, 115: 4251-4262. (2002) IF: 6.954
19. **Nagy P**, Arndt-Jovin DJ, Jovin TM: Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. *Exp Cell Res*, 285:39-49. (2003) IF: 3.949
20. Vereb G, Szöllősi J, Matkó J, **Nagy P**, Farkas T, Vigh L, Mátyus L, Waldmann TA, Damjanovich S: Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model. *Proc Natl Acad Sci USA*, 100: 8053-8058. (2003) IF: 10.272

21. Lidke DS, **Nagy P**, Barisas BG, Heintzmann R, Post JN, Lidke KA, Clayton AHA, Arndt-Jovin DJ, Jovin TM: Imaging molecular interactions in cells by dynamic and static fluorescence anisotropy (rFLIM and emFRET). *Biochem Soc Trans*, 31: 1020-1027. (2003) IF: 2.579
22. Lidke DS, **Nagy P**, Heintzmann R, Arndt-Jovin DJ, Post JN, Greco HE, Jares-Erijman EA, Jovin TM: Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. *Nat Biotechnol*, 22: 198-203. (2004) IF: 22.355
23. **Nagy P**, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. *Cancer Res*, 65: 473-482. (2005) IF: 7.616
24. Mocanu MM, Fazekas Z, Petrás M, **Nagy P**, Sebestyén Z, Isola J, Tímár J, Park JW, Vereb G, Szöllősi J: Associations of ErbB2,  $\beta$ 1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. *Cancer Lett*, 227: 201-212. (2005) IF: 3.049
25. **Nagy P**, Bene L, Hyun WC, Vereb G, Braun M, Antz C, Paysan J, Damjanovich S, Park JW, Szöllősi J: Novel calibration method for flow cytometric fluorescence resonance energy transfer measurements between visible fluorescent proteins. *Cytometry*, 67A: 86-96. (2005) IF: 2.115
26. Friedländer E, Arndt-Jovin DJ, **Nagy P**, Jovin TM, Szöllősi J, Vereb G: Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: Local stimulation using magnetic microspheres as assessed by quantitative digital microscopy. *Cytometry*, 67A: 161-171. (2005) IF: 2.115
27. Vámosi G, Bodnár A, Damjanovich S, **Nagy P**, Varga Z, Damjanovich L: The role of supramolecular protein complexes and membrane potential in transmembrane signaling processes of lymphocytes. *Immunol Lett*, 104: 53-58. (2006) IF: 2.352
28. **Nagy P**, Vámosi G, Damjanovich S, Damjanovich L: ICAM-1 inhibits the homocluster formation of MHC-I in colon carcinoma cells. *Biochem Biophys Res Commun*, 347: 758-763. (2006) IF: 2.855
29. Barok M, Isola J, Pályi-Krekk Z, **Nagy P**, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllősi J: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. *Mol Cancer Ther*, 6: 2065-2072. (2007) IF: 4.8
30. Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllősi J, **Nagy P**: Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. *Eur J Cancer*, 42: 2423-2433. (2007) IF: 4.454

31. Fazekas Z, Petrás M, Fábrián Á, Pályi-Krekk Z, **Nagy P**, Damjanovich S, Vereb G, Szöllősi J: Two-sided fluorescence resonance energy transfer for assessing molecular interactions of up to three distinct species in confocal microscopy. *Cytometry A*, 73A: 209-219. (2008) IF: 3.259
32. Barok M, Balázs M, **Nagy P**, Rákossy Z, Treszl A, Tóth E, Juhász I, Park JW, Isola J, Vereb G, Szöllősi J: Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. *Cancer Lett*, 260: 198-208. (2008) IF: 3.504
33. Pályi-Krekk Z, Márk B, Kovács T, Saya H, Nagano O, Szöllősi J, **Nagy P**: EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. *Cancer Lett*, 263:231-242. (2008) IF: 3.504
34. **Nagy P**, Szöllősi J: Seeing through protein complexes by high-throughput FRET. *Cytometry A*, 73A:388-389. (2008) IF: 3.259
35. Kiss E, **Nagy P**, Balogh A, Szöllősi J, Matkó J: Cytometry of caveola and raft membrane microdomains: from flow and imaging techniques to high throughput screening assays. *Cytometry A*, 73A: 599-614. (2008) IF: 3.259
36. Szabó Á, Horváth G, Szöllősi J, **Nagy P**: Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. *Biophys J*, 95:2086-2096. (2008) IF: 4.683
37. Kovács T, Kárász A, Szöllősi J, **Nagy P**: The density of GM1-enriched lipid rafts correlates inversely with the efficiency of transfection mediated by cationic liposomes. *Cytometry A*, 75A: 650-657. (2009) IF: 3.032
38. **Nagy P**, Szöllősi J: Proximity or no proximity: That is the question-But the answer is more complex. *Cytometry A*, 75A: 813-815. (2009) IF: 3.032
39. Szabó Á, Szöllősi J, **Nagy P**: Cocustering of ErbB1 and ErbB2 revealed by FRET-sensitized acceptor bleaching. *Biophys J*, 99: 105-114. (2010) IF: 4.218
40. **Nagy P**, Claus J, Jovin TM, Arndt-Jovin DJ: Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. *Proc Natl Acad Sci USA*, 107: 16524-16529. (2010) IF: 9.771
41. Mocanu MM, Váradi T, Szöllősi J, **Nagy P**: Comparative analysis of fluorescence resonance energy transfer (FRET) and proximity ligation assay (PLA). *Proteomics*, 11:2063-2070. (2011) IF: 4.505
42. Roszik J, Sebestyén Z, Govers C, Guri Y, Szőőr Á, Pályi-Krekk Z, Vereb G, **Nagy P**, Szöllősi J, Debets R: T-cell synapse formation depends on antigen recognition but not CD3 interaction: Studies with TCR:ζ, a candidate transgene for TCR therapy. *Eur J Immunol*, 41: 1288-1297. (2011) IF: 5.103

43. Váradi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, Galmarini CM, Szöllősi J, **Nagy P**: ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. *Eur J Pharmacol*, 667: 91-99. (2011) IF: 2.516
44. **Nagy P**, Szöllősi J: How to avoid bleeding in Förster resonance energy transfer. *Cytometry A*, 81A: 108-109. (2012) IF: 2.1
45. Váradi T, Mersich T, Auvinen P, Tammi R, Tammi M, Salamon F, Besznyák I Jr, Jakab F, Baranyai Z, Szöllősi J, **Nagy P**: Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan. *J Histochem Cytochem*, 60: 567-575. (2012) IF: 2.255
46. Király A, Váradi T, Hajdu T, Rühl R, Galmarini CM, Szöllősi J, **Nagy P**: Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts. *Mar Drugs*, 11: 4858-4875. (2013) IF: 3.512
47. Mocanu MM, Ganea C, Georgescu L, Váradi T, Shrestha D, Baran I, Katona E, **Nagy P**, Szöllősi J: Epigallocatechin 3-O-gallate induces 67 kDa laminin receptor-mediated cell death accompanied by downregulation of ErbB proteins and altered lipid raft clustering in mammary and epidermoid carcinoma cells. *J Nat Prod*, 77: 250-257. (2014) IF: 3.798
48. **Nagy P**, Szabó Á, Váradi T, Kovács T, Batta B, Szöllősi J: Maximum likelihood estimation of FRET efficiency and its implications for distortions in pixelwise calculation of FRET in microscopy. *Cytometry A*, 85: 942-952. (2014) IF: 2.928
49. Nizsalóczki E, Csomós I, **Nagy P**, Fazekas Z, Goldman CK, Waldmann TA, Damjanovich S, Vámosi G, Mátyus L, Bodnár A: Distinct spatial relationship of the interleukin-9 receptor with interleukin-2 receptor and major histocompatibility complex glycoproteins in human T lymphoma cells. *Chemphyschem*, 15: 3969-3978. (2014) IF: 2.2
50. Shrestha D, Jenei A, **Nagy P**, Vereb G, Szöllősi J: Understanding FRET as a research tool for cellular studies. *Int J Mol Sci*, 16: 6718-6756. (2015) IF: 4.9
51. Mocanu MM, **Nagy P**, Szöllősi J: Chemoprevention of breast cancer by dietary polyphenols. *Molecules*, 20: 22578-22620. (2015) IF: 2.465
52. **Nagy P**, Szabó Á, Váradi T, Kovács T, Batta G, Szöllősi J: rFRET: A comprehensive, Matlab-based program for analyzing intensity-based ratiometric microscopic FRET experiments. *Cytometry A*, 89: 376-384. (2016) IF: 3.222
53. Mocsár G, Volkó J, Rönnlund D, Widengren J, **Nagy P**, Szöllősi J, Tóth K, Goldman CK, Damjanovich S, Waldmann TA, Bodnár A, Vámosi G: MHC I expression regulates co-clustering and mobility of interleukin-2 and -15 receptors in T cells. *Biophys J*, 111: 100-112. (2016) IF: 3.656

54. Szöllősi J, Vereb G, **Nagy P**: The flow of events: How the sequence of molecular interactions is seen by the latest, user-friendly high throughput flow cytometric FRET. *Cytometry A*, 89: 881-885. (2016) IF: 3.222
55. Kovács T, Batta G, Hajdu T, Szabó Á, Váradi T, Zákány F, Csomós I, Szöllősi J, **Nagy P**: The dipole potential modifies the clustering and ligand binding affinity of ErbB proteins and their signaling efficiency. *Sci Rep*, 6: 35850. (2016) IF: 4.259
56. Balogh E, Nagy B Jr, Gyetvai Á, Bene Z, Hendrik Z, Jeney V, **Nagy P**, Papp A, Balla J, Balla G, Kappelmayer J, Nagy B: Impaired immunosuppressive effect of bronchoalveolar mesenchymal stem cells in hypersensitivity pneumonitis: Preliminary findings. *Cytometry B Clin Cytom*, 94: 363-368. (2018) IF: 2.938
57. Tarapcsák S, Szalóki G, Telbisz A, Gyöngy Z, Matúz K, Csósz É, **Nagy P**, Holb IJ, Rühl R, Nagy L, Szabó G, Goda K: Interactions of retinoids with the ABC transporters P-glycoprotein and Breast Cancer Resistance Protein. *Sci Rep*, 7: 41376. (2017) IF: 4.122
58. Mocanu MM, **Nagy P**, Szöllősi J: Detection of protein interactions by Subcellular Localization Assay. *Cytometry A*, 91: 657-658. (2017) IF: 3.26
59. Kovács T, Batta G Jr, Zákány F, Szöllősi J, **Nagy P**: The dipole potential correlates with lipid raft markers in the plasma membrane of living cells. *J Lipid Res*, 58: 1681-1691. (2017) IF: 4.505
60. Filippi A, Picot T, Aanei CM, **Nagy P**, Szöllősi J, Campos L, Ganea C, Mocanu MM: Epigallocatechin-3-O-gallate alleviates the malignant phenotype in A-431 epidermoid and SK-BR-3 breast cancer cell lines. *Int J Food Sci Nutr*. 69: 584-597. (2018) IF: 3.3
61. Batta G, Soltész L, Kovács T, Bozó T, Mészár Z, Kellermayer M, Szöllősi J, **Nagy P**: Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease. *Sci Rep*, 8: 157. (2018) IF: 3.9
62. Szabó Á, Szendi-Szatmári T, Ujlaky-Nagy L, Rádi I, Vereb G, Szöllősi J, **Nagy P**: The effect of fluorophore conjugation on antibody affinity and the photophysical properties of dyes. *Biophys J*, 114: 688-700. (2018) IF: 3.665
63. Nizsalóczki E, **Nagy P**, Mocsár G, Szabó Á, Csomós I, Waldmann TA, Vámosi G, Mátyus L, Bodnár A: Minimum degree of overlap between IL-9R and IL-2R on human T lymphoma cells: A quantitative CLSM and FRET analysis. *Cytometry A*, 93: 1106-1117. (2018) IF: 3.433
64. Zákány F, Pap P, Papp F, Kovács T, **Nagy P**, Péter M, Sente L, Panyi G, Varga Z: Determining the target of membrane sterols on voltage-gated potassium channels. *Biochim Biophys Acta Mol Cell Biol Lipids*, 1864:312-325. (2019) IF: 4.519

65. Costea T, **Nagy P**, Ganea C, Szöllősi J, Mocanu M-M: Molecular mechanisms and bioavailability of polyphenols in prostate cancer. *Int J Mol Sci*, 20: 1062 (2019) IF: 4.556
66. Szendi-Szatmári T, Szabó Á, Szöllősi J, **Nagy P**: Reducing the detrimental effects of saturation phenomena in FRET microscopy. *Anal Chem*. 91: 6378-6382. (2019) IF: 6.785
67. Váradi T, Schneider M, Sevcsik E, Kiesenhofer D, Baumgart F, Batta G, Kovács T, Platzer R, Huppa JB, Szöllősi J, Schütz GJ, Brameshuber M, **Nagy P**: Homo- and heteroassociations drive activation of ErbB3. *Biophys. J*. 117: 1935-1947. (2019) IF: 3.854
68. Szabó Á, Szendi-Szatmári T, Szöllősi J, **Nagy P**: Quo vadis FRET? Förster's method in the era of superresolution. *Methods Appl Fluoresc*. 8: 032003 (2020) IF: 3.009
69. Hajdu T, Váradi T, Rebenku I, Kovács T, Szöllősi J, **Nagy P**: Comprehensive model for epidermal growth factor receptor ligand binding involving conformational states of the extracellular and the kinase domains. *Front Cell Dev Biol*. 8: 776 (2020) IF: 6.684
70. Szabó Á, **Nagy P**: I am the alpha and the ... gamma, and the G. Calibration of intensity-based FRET measurements. *Cytometry A*. 99: 369-371. (2021) IF: 4.714
71. Zákány F, Szabó M, Batta G, Kárpáti L, Mándity MI, Fülöp P, Varga Z, Panyi G, **Nagy P**, Kovács T: An  $\omega$ -3, but not an  $\omega$ -6 polyunsaturated fatty acid decreases membrane dipole potential and stimulates endo-lysosomal escape of penetratin. *Front Cell Dev Biol*. 9: 647300 (2021) IF: 6.081
72. Batta G, Kárpáti L, Henrique GF, Tóth G, Tarapcsák S, Kovács T, Zákány F, Mándity IM, **Nagy P**: Statin-boosted cellular uptake and endosomal escape of penetratin due to reduced membrane dipole potential. *Br. J. Pharmacol*. 178: 3667-3681. (2021) IF: 9.473
73. Hajdu T, Szabó K, Jakab Á, Pócsi I, Dombrádi V, **Nagy P**: Biophysical experiments reveal a protective role of protein phosphatase Z1 against oxidative damage of the cell membrane in *Candida albicans*. *Free Rad Biol Med*. 176: 222-227. (2021) IF: 8.101
74. Kovács T, Sohajda T, Sente L, **Nagy P**, Panyi G, Varga Z, Zákány F: Cyclodextrins exert a ligand-like current inhibitory effect on the Kv1.3 ion channel independent of membrane cholesterol extraction. *Front Mol Biosci*. 8: 735357. (2021) IF: 6.113
75. Csomós I, **Nagy P**, Filep C, Rebenku I, Nizsalóczki E, Kovács T, Vámosi G, Mátyus L, Bodnár A. Opposing effects of chelidonine on tyrosine and serine phosphorylation of STAT3 in human uveal melanoma cells. *Int J Mol Sci*. 22: 12974. (2021) IF: 6.208

76. Kovács T, Zákány F, **Nagy P**: It takes more than two to tango: complex, hierarchal, and membrane-modulated interactions in the regulation of receptor tyrosine kinases. *Cancers* 14: 944 (2022) IF: 5.2
77. Imre L, Niaki EF, Bosire R, Nánási P Jr, **Nagy P**, Bacsó Z, Hamidova N, Pommier Y, Jordan A, Szabó G: Nucleosome destabilization by polyamines. *Arch Biochem Biophys.* 722: 109184 (2022) IF: 3.9
78. Kovács T, **Nagy P**, Panyi G, Sente L, Varga Z, Zákány F: Cyclodextrins: only pharmaceutical excipients or full-fledged drug candidates? *Pharmaceutics*, 14: 2559 (2022) IF: 5.4
79. Yousef M, Szabó I, Murányi J, Illien F, Soltész D, Bató C, Tóth G, Batta G, **Nagy P**, Sagan S, Bánóczy Z: Cell-penetrating dabcyll-containing tetraarginines with backbone aromatics as uptake enhancers, *Pharmaceutics*, 15: 141 (2023) IF: 4.9
80. Kovács T, Kurtán K, Varga Z, **Nagy P**, Panyi G, Zákány F: Veklury® (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether- $\beta$ -cyclodextrin content. *Br J Pharmacol*, 180: 2064-2084 (2023) IF: 6.8
81. Batta A, Hajdu T, **Nagy P**: Improved estimation of the ratio of detection efficiencies of excited acceptors and donors for FRET measurements. *Cytometry A*, 103: 563-574 (2023) IF: 2.5
82. Zakany F, Mandity IM, Varga Z, Panyi G, **Nagy P**, Kovacs T: Effect of the lipid landscape on the efficacy of cell-penetrating peptides. *Cells*, 12: 1700 (2023) IF: 5.1
83. Ujlaki G, Kovács T, Vida A, Kókai E, Rauch B, Schwarcz S, Mikó E, Janka E, Sipos A, Hegedős C, Uray K, **Nagy P**, Bai P: Identification of bacterial metabolites modulating breast cancer cell proliferation and epithelial-mesenchymal transition. *Molecules*, 28: 5898 (2023) IF: 4.2
84. Szabó CB, Szabó M, **Nagy P**, Varga Z, Panyi G, Kovács T, Zákány F: Novel insights into the modulation of the voltage-gated potassium channel KV1.3 gating by membrane ceramides. *J Lipid Res*, 65: 100596 (2024) IF: 4.1
85. Kovács T, Szabó CB, Kothalawala RC, Székelyhidi V, Nagy P, Varga Z, Panyi G, Zákány F: Inhibition of the H<sub>v</sub>1 voltage-gated proton channel compromises the viability of human polarized macrophages in a polarization- and ceramide-dependent manner. *Front Immunol*, 15: 1487578 (2024) IF: 5.9
86. Szabó M, Szabó CB, Kurtán K, Varga Z, Panyi G, **Nagy P**, Zákány F, Kovács T: Look beyond plasma membrane biophysics: revealing considerable variability of the dipole potential between plasma and organelle membranes of living cells. *Int J Mol Sci*, 26: 889 (2025) IF: 4.9

87. Szabó Á, Tóth G, Szatmári T, Mocsár G, Rebenku I, Szöllősi J, **Nagy P**: Local ligand concentration gradients induced by the plasma membrane. *iScience*, 28:112954 (2025) IF: 4.1
88. Hajdu T, Rebenku I, Serrano Cano TG, Mocsár G, Bécsi B, Erdődi F, **Nagy P**: Fluorescence labeling-induced structural rearrangement of a monoclonal IgG revealed by biophysical experiments and simulations. *Int J Biol Macromol*, 321: 146209 (2025) IF: 8.5